| Literature DB >> 33832478 |
Kavita Singh1,2, Dimple Kondal3, Sailesh Mohan3,4,5, Suganthi Jaganathan4, Mohan Deepa6, Nikhil Srinivasapura Venkateshmurthy3,4, Prashant Jarhyan3, Ranjit Mohan Anjana6, K M Venkat Narayan7, Viswanathan Mohan6, Nikhil Tandon8, Mohammed K Ali7, Dorairaj Prabhakaran3,4,9, Karen Eggleston10.
Abstract
BACKGROUND: People with chronic conditions are disproportionately prone to be affected by the COVID-19 pandemic but there are limited data documenting this. We aimed to assess the health, psychosocial and economic impacts of the COVID-19 pandemic on people with chronic conditions in India.Entities:
Keywords: COVID-19 pandemic; Chronic conditions; India; SARS coronavirus
Mesh:
Year: 2021 PMID: 33832478 PMCID: PMC8027966 DOI: 10.1186/s12889-021-10708-w
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Characteristics of study participants by demographic and socio-economic status, clinical history and COVID-19 status
| Overall ( | Delhi ( | Chennai ( | Sonipat ( | Vizag ( | ||||
|---|---|---|---|---|---|---|---|---|
| Rural ( | Urban ( | Rural ( | Urban ( | |||||
| Age, years (mean, SD) | 57.8 (11.3) | 57.8 (11.0) | 57.5 (11.6) | 56.6 (11.4) | 58.5 (10.8) | 57.1 (10.2) | 59.8 (11.9) | 0.055 |
| Male (%) | 861 (49.7%) | 219 (50.9%) | 247 (50.0%) | 86 (41.1%) | 97 (48.3%) | 92 (47.9%) | 120 (57.7%) | 0.033 |
| Ownership of mobile phone | 1366 (78.8%) | 398 (92.6%) | 382 (77.3%) | 118 (56.5%) | 123 (61.2%) | 152 (79.2%) | 193 (92.8%) | < 0.001 |
| Internet use/access | 741 (42.7%) | 341 (79.3%) | 175 (35.4%) | 16 (7.7%) | 50 (24.9%) | 34 (17.7%) | 125 (60.1%) | < 0.001 |
| Below primary school | 293 (16.9%) | 43 (10.0%) | 36 (7.3%) | 57 (27.3%) | 41 (20.4%) | 93 (48.4%) | 23 (11.1%) | < 0.001 |
| Primary school | 119 (6.9%) | 9 (2.1%) | 40 (8.1%) | 10 (4.8%) | 18 (9.0%) | 28 (14.6%) | 14 (6.7%) | |
| Secondary school | 978 (56.4%) | 219 (50.9%) | 372 (75.3%) | 135 (64.6%) | 97 (48.3%) | 65 (33.9%) | 90 (43.3%) | |
| College degree and above | 342 (19.7%) | 157 (36.5%) | 46 (9.3%) | 7 (3.3%) | 45 (22.4%) | 6 (3.1%) | 81 (38.9%) | |
| < 10,000 INR | 540 (31.1%) | 51 (11.9%) | 235 (47.6%) | 96 (45.9%) | 32 (15.9%) | 115 (59.9%) | 11 (5.3%) | < 0.001 |
| 10,000–30,000 INR | 732 (42.2%) | 169 (39.3%) | 238 (48.2%) | 77 (36.8%) | 97 (48.3%) | 64 (33.3%) | 87 (41.8%) | |
| > 30,000 INR | 431 (24.9%) | 208 (48.4%) | 21 (4.3%) | 29 (13.9%) | 52 (25.9%) | 12 (6.3%) | 109 (52.4%) | |
| Not working | 1004 (57.9%) | 259 (60.2%) | 273 (55.3%) | 137 (65.6%) | 129 (64.2%) | 86 (44.8%) | 120 (57.7%) | < 0.001 |
| Semiskilled/Unskilled | 262 (15.1%) | 26 (6.0%) | 127 (25.7%) | 30 (14.4%) | 23 (11.4%) | 37 (19.3%) | 19 (9.1%) | |
| Trained/Skilled | 456 (26.3%) | 139 (32.3%) | 91 (18.4%) | 42 (20.1%) | 49 (24.4%) | 69 (35.9%) | 66 (31.7%) | |
| White collar | 12 (0.7%) | 6 (1.4%) | 3 (0.6%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 3 (1.4%) | |
| BMI (Kg/m2), mean (SD) | 26.8 (5.1) | 27.8 (5.1) | 26.8 (4.9) | 26.1 (5) | 27.2 (5.4) | 23.7 (4.4) | 27 (4.3) | < 0.001 |
| Diabetes mellitusa | 743 (42.8%) | 180 (41.9%) | 255 (51.6%) | 35 (16.7%) | 88 (43.8%) | 49 (25.5%) | 136 (65.4%) | < 0.001 |
| Hypertensionb | 975 (56.2%) | 202 (47.0%) | 210 (42.5%) | 154 (73.7%) | 104 (51.7%) | 152 (79.2%) | 153 (73.6%) | < 0.001 |
| Cardiovascular disease | 229 (13.2%) | 47 (10.9%) | 38 (7.7%) | 57 (27.3%) | 35 (17.4%) | 20 (10.4%) | 32 (15.4%) | < 0.001 |
| Chronic kidney disease | 43 (2.5%) | 9 (2.1%) | 6 (1.2%) | 12 (5.7%) | 2 (1.0%) | 7 (3.6%) | 7 (3.4%) | 0.006 |
| Chronic obstructive pulmonary disease | 18 (1.0%) | 4 (0.9%) | 2 (0.4%) | 2 (1.0%) | 1 (0.5%) | 4 (2.1%) | 5 (2.4%) | 0.14 |
| Participant diagnosed or treated for COVID-19 | 46 (2.7%) | 18 (4.2%) | 6 (1.2%) | 13 (6.2%) | 5 (2.5%) | 2 (1.0%) | 2 (1.0%) | 0.003 |
| Hospitalized for COVID-19 | 13 (0.7%) | 4 (0.9%) | 6 (1.2%) | 0 (0.0%) | 1 (0.5%) | 1 (0.5%) | 1 (0.5%) | < 0.001 |
| Number of days hospitalized, median (IQR) | 10.0 (8.0, 14.0) | 13.0 (8.0, 14.0) | 8.5 (8.0, 10.0) | na | 10.0 (10.0, 10.0) | 14.0 (14.0, 14.0) | 14.0 (14.0, 14.0) | 0.44 |
| Immediate family members diagnosed/treated for COVID-19 | 52 (3.0%) | 16 (3.7%) | 13 (2.6%) | 11 (5.3%) | 8 (4.0%) | 1 (0.5%) | 3 (1.4%) | 0.13 |
| Any confirmed cases of COVID-19 in other households in your locality | 1192 (68.7%) | 265 (61.6%) | 401 (81.2%) | 111 (53.1%) | 110 (54.7%) | 123 (64.1%) | 182 (87.5%) | < 0.001 |
| Experienced fear/anxiety related to COVID-19 | 1029 (59.3%) | 267 (62.1%) | 148 (30.0%) | 208 (99.5%) | 131 (65.2%) | 134 (69.8%) | 141 (67.8%) | < 0.001 |
| Experienced stigma related to COVID-19 | 15 (0.9%) | 8 (1.9%) | 2 (0.4%) | 4 (1.9%) | 1 (0.5%) | 0 (0.0%) | 0 (0.0%) | 0.17 |
| Very well | 254 (14.6%) | 77 (17.9%) | 68 (13.8%) | 44 (21.1%) | 37 (18.4%) | 6 (3.1%) | 22 (10.6%) | < 0.001 |
| Moderate | 850 (49.0%) | 190 (44.2%) | 160 (32.4%) | 164 (78.5%) | 158 (78.6%) | 92 (47.9%) | 86 (41.3%) | |
| With difficulty | 281 (16.2%) | 93 (21.6%) | 40 (8.1%) | 0 (0.0%) | 4 (2.0%) | 70 (36.5%) | 74 (35.6%) | |
| No Stress | 349 (20.1%) | 70 (16.3%) | 226 (45.7%) | 1 (0.5%) | 2 (1.0%) | 24 (12.5%) | 26 (12.5%) | |
BMI Body mass Index, IQR interquartile range (p25, p75), INR Indian rupees, SD standard deviation, COVID-19 coronavirus disease 2019
*p value reported for between group difference across study sites
aDiabetes is defined based on fasting plasma glucose (FPG) > =126 mg/dl (7.0 mmol/l) and/or glycated haemoglobin (HbA1c) > = 6.5% (48 mmol/mol) or self-reported or on anti-diabetic medications. bHypertension was defined as being on antihypertensive medications or a systolic blood pressure > =140 mmHg and/or a diastolic blood pressure > =90 mmHg. Cardiovascular disease and chronic kidney disease were self-reported and/or on medications
Fig. 1COVID-19 pandemic impacts on urban and rural people living with chronic conditions in India
Impact of COVID-19 pandemic on health, healthcare access, treatment satisfaction and achievement of care goals
| Overall ( | Delhi ( | Chennai ( | Sonipat ( | Vizag ( | ||||
|---|---|---|---|---|---|---|---|---|
| Rural ( | Urban ( | Rural ( | Urban ( | |||||
| Experienced acute medical illness during the COVID-19 lockdown | 142 (8.2%) | 25 (5.8%) | 25 (5.1%) | 31 (14.8%) | 11 (5.5%) | 26 (13.5%) | 24 (11.5%) | < 0.001 |
| Difficulty in accessing healthcare facility during COVID-19 lockdown | 118 (83.1) | 20 (80) | 16 (64) | 31 (100) | 8 (72.7) | 23 (88.5) | 20 (83.3) | 0.014 |
| Experienced difficulties in accessing medicines due to COVID-19 situation | 293 (16.9%) | 27 (6.3%) | 47 (9.5%) | 69 (33.0%) | 15 (7.5%) | 79 (41.1%) | 56 (26.9%) | |
| Diabetes mellitus | 134 (18.0%) | 17 (9.4%) | 36 (14.1%) | 11 (31.4%) | 7 (8.0%) | 24 (49.0%) | 39 (28.7%) | 0.24 |
| Hypertension | 198 (20.3%) | 13 (6.4%) | 20 (9.5%) | 53 (34.4%) | 11 (10.6%) | 60 (39.5%) | 41 (26.8%) | < 0.001 |
| Cardiovascular disease | 35 (15.3%) | 1 (2%) | 7 (18%) | 16 (28%) | 0 (0%) | 4 (20%) | 7 (22%) | 0.002 |
| Chronic kidney disease | 7 (16%) | 2 (22%) | 1 (17%) | 3 (25%) | 0 (0%) | 0 (0%) | 1 (14%) | 0.59 |
| COPD | 2 (11%) | 0 (0%) | 1 (50%) | 1 (50%) | 0 (0%) | 0 (0%) | 0 (0%) | 0.22 |
| Experienced difficulties in accessing medicines or treatment due to financial reasons | 258 (14.9%) | 16 (3.7%) | 58 (11.7%) | 36 (17.2%) | 10 (5.0%) | 88 (45.8%) | 50 (24.0%) | |
| Diabetes mellitus | 124 (16.7%) | 12 (6.7%) | 44 (17.3%) | 7 (20.0%) | 4 (4.5%) | 23 (46.9%) | 34 (25.0%) | 0.75 |
| Hypertension | 162 (16.6%) | 7 (3.5%) | 28 (13.3%) | 21 (13.6%) | 7 (6.7%) | 70 (46.1%) | 29 (19.0%) | 0.004 |
| Cardiovascular disease | 25 (10.9%) | 0 (0%) | 3 (8%) | 9 (16%) | 0 (0%) | 5 (25%) | 8 (25%) | 0.10 |
| Chronic kidney disease | 4 (9%) | 1 (11%) | 0 (0%) | 2 (17%) | 0 (0%) | 0 (0%) | 1 (14%) | 0.52 |
| Chronic obstructive pulmonary lung disease | 2 (11%) | 0 (0%) | 0 (0%) | 1 (50%) | 0 (0%) | 0 (0%) | 1 (20%) | |
| Functioning local health clinic/hospital during lockdown | 1175 (67.8%) | 329 (76.5%) | 337 (68.2%) | 153 (73.2%) | 159 (79.1%) | 91 (47.4%) | 106 (51.0%) | < 0.001 |
| Treatment satisfaction during lockdown | 331 (19.1%) | 96 (22.3%) | 181 (36.6%) | 3 (1.4%) | 24 (11.9%) | 11 (5.7%) | 16 (7.7%) | |
| Minimal anxiety | 1497 (86.3%) | 403 (93.7%) | 451 (91.3%) | 196 (93.8%) | 194 (96.5%) | 115 (59.9%) | 138 (66.3%) | < 0.001 |
| Mild anxiety | 181 (10.4%) | 25 (5.8%) | 38 (7.7%) | 11 (5.3%) | 7 (3.5%) | 60 (31.3%) | 40 (19.2%) | |
| Moderate anxiety | 34 (2.0%) | 1 (0.2%) | 4 (0.8%) | 1 (0.5%) | 0 (0.0%) | 10 (5.2%) | 18 (8.7%) | |
| Severe anxiety | 22 (1.3%) | 1 (0.2%) | 1 (0.2%) | 1 (0.5%) | 0 (0.0%) | 7 (3.6%) | 12 (5.8%) | |
| 76.1 (15.3) (n = 1734) | 77.1 (16.5) | 78.4 (15.7) | 78.4 (15.6) | 72.7 (16.3) | 71.1 (11.1) | 74.0 (11.7) | < 0.001 | |
| Mobility (moderate/severe problems) | 360 (20.8%) | 91 (21.2%) | 78 (15.8%) | 60 (28.7%) | 58 (28.9%) | 45 (23.4%) | 28 (13.5%) | |
| Self-care (moderate/severe problems) | 136 (7.8%) | 23 (5.3%) | 41 (8.3%) | 16 (7.7%) | 29 (14.4%) | 14 (7.3%) | 13 (6.3%) | |
| Usual care (moderate/severe problems) | 223 (12.9%) | 31 (7.2%) | 59 (11.9%) | 38 (18.2%) | 39 (19.4%) | 29 (15.1%) | 27 (13.0%) | |
| Pain/discomfort (moderate/severe problems) | 448 (25.8%) | 135 (31.4%) | 70 (14.2%) | 79 (37.8%) | 70 (34.8%) | 56 (29.2%) | 38 (18.3%) | |
| Anxiety/depression (moderate/severe problems) | 314 (18.1%) | 58 (13.5%) | 83 (16.8%) | 46 (22.0%) | 41 (20.4%) | 51 (26.6%) | 35 (16.8%) | |
| Fasting blood sugar tested during the lockdown | 414 (55.7%) | 130 (72.2%) | 151 (59.2%) | 13 (37.1%) | 37 (42.0%) | 17 (34.7%) | 66 (48.5%) | < 0.001 |
| HbA1c tested during the lockdown | 35 (4.7%) | 10 (5.6%) | 8 (3.1%) | 0 (0.0%) | 4 (4.5%) | 0 (0.0%) | 13 (9.6%) | < 0.001 |
| Fasting blood sugar, mean (SD) | 166.6 (71.8) | 158.0 (64.5) | 185.9 (83.1) | 287.3 (83.6) | 137.4 (32.1) | 197.1 (63.4) | 139.7 (44.2) | < 0.001 |
| Fasting blood sugar > 160–200 mg/dl | 51 (17.9) | 19 (16.2) | 18 (19.6) | 1 (16.7) | 3 (30) | 3 (42.9) | 7 (13.2) | |
| Fasting blood sugar > 200 mg/dl | 55 (19.3) | 17 (14.5) | 29 (31.5) | 5 (83.3) | 0 (0) | 2 (28.6) | 2 (3.8) | |
| Blood sugar controlled (perceived) | 230 (31.0%) | 35 (19.4%) | 87 (34.1%) | 16 (45.7%) | 19 (21.6%) | 27 (55.1%) | 46 (33.8%) | < 0.001 |
| Diabetes symptoms worsened during the lockdown | 97 (13.1%) | 33 (18.3%) | 23 (9.0%) | 8 (22.9%) | 9 (10.2%) | 8 (16.3%) | 16 (11.8%) | < 0.001 |
| Glucose monitoring frequency at home | ||||||||
| Once in month | 83 (11.2%) | 43 (23.9%) | 13 (5.1%) | 2 (5.7%) | 16 (18.2%) | 1 (2.0%) | 8 (5.9%) | |
| Do not monitor glucose at home | 530 (71.3%) | 70 (38.9%) | 223 (87.5%) | 33 (94.3%) | 62 (70.5%) | 46 (93.9%) | 96 (70.6%) | |
| Blood pressure measured during the lockdown | 515 (52.8%) | 137 (67.8%) | 127 (60.5%) | 70 (45.5%) | 39 (37.5%) | 53 (34.9%) | 89 (58.2%) | < 0.001 |
| Systolic blood pressure, mean (SD) | 139.0 (20.3) | 142.5 (18.8) | 135.4 (19.4) | 152.2 (29.7) | 140.3 (19.2) | 133.3 (19.5) | 132.2 (14.2) | < 0.001 |
| Diastolic blood pressure, mean (SD) | 86.9 (13.5) | 88.7 (11.1) | 84.6 (11.0) | 91.8 (25.9) | 85.8 (17.0) | 84.8 (11.3) | 84.6 (7.1) | 0.042 |
| SBP ≤140 mmHg | 271 (74.6%) | 79 (69.9%) | 38 (67.9%) | 22 (56.4%) | 27 (75.0%) | 25 (86.2%) | 80 (88.9%) | 0.008 |
| SBP > 140–160 mmHg | 57 (15.7%) | 19 (16.8%) | 12 (21.4%) | 9 (23.1%) | 6 (16.7%) | 3 (10.3%) | 8 (8.9%) | |
| SBP > 160 mmHg | 35 (9.6%) | 15 (13.3%) | 6 (10.7%) | 8 (20.5%) | 3 (8.3%) | 1 (3.4%) | 2 (2.2%) | |
| Blood pressure controlled (perceived) | 142 (14.6%) | 18 (8.9%) | 65 (31.0%) | 24 (15.6%) | 5 (4.8%) | 21 (13.8%) | 9 (5.9%) | 0.022 |
| Symptoms of hypertension worsened during the lockdown | 120 (12.3%) | 42 (20.8%) | 6 (2.9%) | 38 (24.7%) | 8 (7.7%) | 13 (8.6%) | 13 (8.5%) | < 0.001 |
Diabetes is defined based on fasting plasma glucose (FPG) > =126 mg/dl (7.0 mmol/l) and/or glycated haemoglobin (HbA1c) > = 6.5% (48 mmol/mol) or self-reported or on anti-diabetic medications. Hypertension was defined as being on antihypertensive medications or a systolic blood pressure > =140 mmHg and/or a diastolic blood pressure > =90 mmHg. Cardiovascular disease and chronic kidney disease were self-reported and/or on medications
HbA1c glycated haemoglobin, COPD chronic obstructive pulmonary lung disease, EQ-VAS European Quality of Life 5-dimension, Visual analogue scale, SBP systolic blood pressure, DBP diastolic blood pressure, SD standard deviation, INR Indian rupees, COVID-19 coronavirus disease 2019, mmHg millimoles of mercury
*p value reported for between group difference across study sites
Fig. 2Factors associated with difficulty in accessing medicines due to the COVID-19 situation. Diabetes is defined based on fasting plasma glucose (FPG) > =126 mg/dl (7.0 mmol/l) and/or glycated haemoglobin (HbA1c) > = 6.5% (48 mmol/mol) or self-reported or on anti-diabetic medications. Hypertension was defined as being on antihypertensive medications or a systolic blood pressure > =140 mmHg and/or a diastolic blood pressure > =90 mmHg. Cardiovascular disease and chronic kidney disease were self-reported and/or on medications. INR = Indian rupees, CVD = cardiovascular disease, Kidney = chronic kidney disease, 95% CI = confidence interval
Fig. 3Factors associated with worsening of diabetes or hypertension symptoms during the COVID-19 lockdown. Diabetes is defined based on fasting plasma glucose (FPG) > =126 mg/dl (7.0 mmol/l) and/or glycated haemoglobin (HbA1c) > = 6.5% (48 mmol/mol) or self-reported or on anti-diabetic medications. Hypertension was defined as being on antihypertensive medications or a systolic blood pressure > =140 mmHg and/or a diastolic blood pressure > =90 mmHg. INR = Indian rupees, COVID-19 = coronavirus disease 2019, 95% CI = confidence interval
Social and economic consequences of COVID-19 pandemic
| Overall ( | Delhi ( | Chennai ( | Sonipat ( | Vizag ( | |||
|---|---|---|---|---|---|---|---|
| Impact on self-care behaviors | Rural ( | Urban ( | Rural ( | Urban ( | |||
| Adherence to a meal plan in the last 1 week | |||||||
| 0 days | 553 (36.2) | 179 (51.6) | 227 (54.7) | 48 (25) | 46 (25) | 37 (20) | 16 (7.8) |
| 1–3 days | 157 (10.3) | 4 (1.2) | 0 (0) | 52 (27.1) | 57 (31) | 26 (14.1) | 18 (8.7) |
| 4 or more days | 819 (53.6) | 164 (47.3) | 188 (45.3) | 92 (47.9) | 81 (44) | 122 (66) | 172 (83.5) |
| Irregular eating pattern in the last 1 week | |||||||
| 0 days | 1365 (78.7) | 388 (90.2) | 456 (92.3) | 126 (60.3) | 116 (57.7) | 134 (69.8) | 145 (69.7) |
| 1–3 days | 249 (14.4) | 32 (7.4) | 25 (5.1) | 39 (18.7) | 60 (29.9) | 44 (22.9) | 49 (23.6) |
| 4 or more days | 120 (6.9) | 10 (2.3) | 13 (2.6) | 44 (21.1) | 25 (12.4) | 14 (7.3) | 14 (6.7) |
| Physical activity in the last 1 week | |||||||
| 0 days | 1038 (59.9) | 332 (77.2) | 338 (68.4) | 54 (25.8) | 90 (44.8) | 122 (63.5) | 102 (49) |
| 1–3 days | 202 (11.7) | 36 (8.4) | 12 (2.4) | 83 (39.7) | 54 (26.9) | 7 (3.7) | 10 (4.8) |
| 4 or more days | 494 (28.5) | 62 (14.4) | 144 (29.2) | 72 (34.5) | 57 (28.4) | 63 (32.8) | 96 (46.2) |
| Fruits consumption during lockdown vs. pre-lockdown | |||||||
| Reduced fruit intake | 658 (37.9%) | 77 (17.9%) | 153 (31.0%) | 198 (94.7%) | 94 (46.8%) | 78 (40.6%) | 58 (27.9%) |
| Increased fruit intake | 105 (6.1%) | 40 (9.3%) | 10 (2.0%) | 1 (0.5%) | 5 (2.5%) | 13 (6.8%) | 36 (17.3%) |
| No change in fruit intake | 971 (56.0%) | 313 (72.8%) | 331 (67.0%) | 10 (4.8%) | 102 (50.7%) | 101 (52.6%) | 114 (54.8%) |
| Vegetables consumption during lockdown vs. pre-lockdown | |||||||
| Reduced vegetable intake | 485 (28.0%) | 49 (11.4%) | 67 (13.6%) | 191 (91.4%) | 81 (40.3%) | 61 (31.8%) | 36 (17.3%) |
| Increased vegetable intake | 196 (11.3%) | 46 (10.7%) | 39 (7.9%) | 2 (1.0%) | 8 (4.0%) | 35 (18.2%) | 66 (31.7%) |
| No change in vegetable intake | 1053 (60.7%) | 335 (77.9%) | 388 (78.5%) | 16 (7.7%) | 112 (55.7%) | 96 (50.0%) | 106 (51.0%) |
| Duration and intensity of physical activity during lockdown vs. pre-lockdown | |||||||
| Decreased physical activity | 431 (24.9%) | 42 (9.8%) | 111 (22.5%) | 149 (71.3%) | 89 (44.3%) | 10 (5.2%) | 30 (14.4%) |
| Increased physical activity | 38 (2.2%) | 10 (2.3%) | 11 (2.2%) | 2 (1.0%) | 8 (4.0%) | 0 (0.0%) | 7 (3.4%) |
| No change in physical activity | 227 (13.1%) | 46 (10.7%) | 34 (6.9%) | 4 (1.9%) | 14 (7.0%) | 60 (31.3%) | 69 (33.2%) |
| Experienced loss of job | 634 (36.6%) | 163 (37.9%) | 212 (42.9%) | 86 (41.1%) | 75 (37.3%) | 49 (25.5%) | 49 (23.6%) |
| Experienced loss of income | 1029 (59.3%) | 203 (47.2%) | 355 (71.9%) | 131 (62.7%) | 91 (45.3%) | 139 (72.4%) | 110 (52.9%) |
| Received financial support from the government | 774 (44.6%) | 36 (8.4%) | 460 (93.1%) | 34 (16.3%) | 14 (7.0%) | 163 (84.9%) | 67 (32.2%) |
COVID-19 coronavirus disease 2019